Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Treating insect-bite hypersensitivity in horses with active vaccination against IL-5.

Fettelschoss-Gabriel A, Fettelschoss V, Thoms F, Giese C, Daniel M, Olomski F, Kamarachev J, Birkmann K, Bühler M, Kummer M, Zeltins A, Marti E, Kündig TM, Bachmann MF.

J Allergy Clin Immunol. 2018 Mar 28. pii: S0091-6749(18)30291-4. doi: 10.1016/j.jaci.2018.01.041. [Epub ahead of print]

2.

Vaccination against IL-31 for the treatment of atopic dermatitis in dogs.

Bachmann MF, Zeltins A, Kalnins G, Balke I, Fischer N, Rostaher A, Tars K, Favrot C.

J Allergy Clin Immunol. 2018 Mar 28. pii: S0091-6749(18)30118-0. doi: 10.1016/j.jaci.2017.12.994. [Epub ahead of print] No abstract available.

PMID:
29627081
3.

An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcγRIIb.

Zha L, Leoratti FMS, He L, Mohsen MO, Cragg M, Storni F, Vogel M, Bachmann MF.

J Allergy Clin Immunol. 2018 Jan 31. pii: S0091-6749(18)30037-X. doi: 10.1016/j.jaci.2017.09.054. [Epub ahead of print]

PMID:
29391255
4.

Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy.

Zeltins A, West J, Zabel F, El Turabi A, Balke I, Haas S, Maudrich M, Storni F, Engeroff P, Jennings GT, Kotecha A, Stuart DI, Foerster J, Bachmann MF.

NPJ Vaccines. 2017 Oct 23;2:30. doi: 10.1038/s41541-017-0030-8. eCollection 2017.

5.

A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentation.

Engeroff P, Fellmann M, Yerly D, Bachmann MF, Vogel M.

J Allergy Clin Immunol. 2017 Oct 23. pii: S0091-6749(17)31591-9. doi: 10.1016/j.jaci.2017.09.024. [Epub ahead of print]

PMID:
29074459
6.

Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.

Cabral-Miranda G, Heath MD, Gomes AC, Mohsen MO, Montoya-Diaz E, Salman AM, Atcheson E, Skinner MA, Kramer MF, Reyes-Sandoval A, Bachmann MF.

Vaccines (Basel). 2017 Sep 27;5(4). pii: E32. doi: 10.3390/vaccines5040032.

7.

Major findings and recent advances in virus-like particle (VLP)-based vaccines.

Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF.

Semin Immunol. 2017 Dec;34:123-132. doi: 10.1016/j.smim.2017.08.014. Epub 2017 Sep 5. Review.

PMID:
28887001
8.

Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.

Doucet M, El-Turabi A, Zabel F, Hunn BHM, Bengoa-Vergniory N, Cioroch M, Ramm M, Smith AM, Gomes AC, Cabral de Miranda G, Wade-Martins R, Bachmann MF.

PLoS One. 2017 Aug 10;12(8):e0181844. doi: 10.1371/journal.pone.0181844. eCollection 2017.

9.

Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells.

Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF.

Allergy. 2018 Feb;73(2):341-349. doi: 10.1111/all.13268. Epub 2017 Sep 12.

PMID:
28787769
10.

Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.

Leneghan DB, Miura K, Taylor IJ, Li Y, Jin J, Brune KD, Bachmann MF, Howarth M, Long CA, Biswas S.

Sci Rep. 2017 Jun 19;7(1):3811. doi: 10.1038/s41598-017-03798-3.

11.

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.

Cabral-Miranda G, Heath MD, Mohsen MO, Gomes AC, Engeroff P, Flaxman A, Leoratti FMS, El-Turabi A, Reyes-Sandoval A, Skinner MA, Kramer MF, Bachmann MF.

Vaccines (Basel). 2017 May 2;5(2). pii: E10. doi: 10.3390/vaccines5020010.

12.

Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines.

Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi AE, Manolova V, Bachmann MF.

Front Immunol. 2017 Mar 6;8:226. doi: 10.3389/fimmu.2017.00226. eCollection 2017.

13.

Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.

Mohsen MO, Gomes AC, Cabral-Miranda G, Krueger CC, Leoratti FM, Stein JV, Bachmann MF.

J Control Release. 2017 Apr 10;251:92-100. doi: 10.1016/j.jconrel.2017.02.031. Epub 2017 Feb 28.

PMID:
28257987
14.

Harnessing Nanoparticles for Immunomodulation and Vaccines.

Gomes AC, Mohsen M, Bachmann MF.

Vaccines (Basel). 2017 Feb 14;5(1). pii: E6. doi: 10.3390/vaccines5010006. Review.

15.

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.

Alves E, Salman AM, Leoratti F, Lopez-Camacho C, Viveros-Sandoval ME, Lall A, El-Turabi A, Bachmann MF, Hill AV, Janse CJ, Khan SM, Reyes-Sandoval A.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00501-16. doi: 10.1128/CVI.00501-16. Print 2017 Apr.

16.

Detecting circulating antibodies by controlled surface modification with specific target proteins: Application to malaria.

Cardoso AR, Cabral-Miranda G, Reyes-Sandoval A, Bachmann MF, Sales MGF.

Biosens Bioelectron. 2017 May 15;91:833-841. doi: 10.1016/j.bios.2017.01.031. Epub 2017 Jan 15.

PMID:
28157657
17.

Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation.

Zabel F, Fettelschoss A, Vogel M, Johansen P, Kündig TM, Bachmann MF.

Immunology. 2017 Mar;150(3):329-342. doi: 10.1111/imm.12688. Epub 2017 Jan 5.

18.

The True Story and Advantages of RNA Phage Capsids as Nanotools.

Pumpens P, Renhofa R, Dishlers A, Kozlovska T, Ose V, Pushko P, Tars K, Grens E, Bachmann MF.

Intervirology. 2016;59(2):74-110. doi: 10.1159/000449503. Epub 2016 Nov 10. Review.

19.

Allergen-specific immunotherapy: is it vaccination against toxins after all?

Bachmann MF, Kündig TM.

Allergy. 2017 Jan;72(1):13-23. doi: 10.1111/all.12890. Epub 2016 Sep 28. Review.

PMID:
27558586
20.

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.

Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M.

Sci Rep. 2016 Jan 19;6:19234. doi: 10.1038/srep19234.

21.

Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes.

Cavelti-Weder C, Timper K, Seelig E, Keller C, Osranek M, Lässing U, Spohn G, Maurer P, Müller P, Jennings GT, Willers J, Saudan P, Donath MY, Bachmann MF.

Mol Ther. 2016 May;24(5):1003-12. doi: 10.1038/mt.2015.227. Epub 2015 Dec 21.

22.

Is The Allergen Really Needed in Allergy Immunotherapy?

Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF.

Curr Treat Options Allergy. 2015;2(1):72-82. Review.

23.

Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.

Dallenbach K, Maurer P, Röhn T, Zabel F, Kopf M, Bachmann MF.

Eur J Immunol. 2015 Apr;45(4):1238-47. doi: 10.1002/eji.201445017. Epub 2015 Jan 23.

24.

Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.

Klimek L, Bachmann MF, Senti G, Kündig TM.

Expert Rev Clin Immunol. 2014 Aug;10(8):1059-67. doi: 10.1586/1744666X.2014.924854. Epub 2014 Jun 5. Review.

PMID:
24898577
25.

Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies.

Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kündig TM, Bachmann MF.

J Immunol. 2014 Jun 15;192(12):5499-508. doi: 10.4049/jimmunol.1400065. Epub 2014 May 12.

26.

Vaccination against Alzheimer disease: an update on future strategies.

Fettelschoss A, Zabel F, Bachmann MF.

Hum Vaccin Immunother. 2014;10(4):847-51. Epub 2014 Feb 17. Review.

27.

Intralymphatic immunotherapy: time interval between injections is essential.

Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G.

J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15. No abstract available.

PMID:
24439076
28.

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes.

Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF.

Mol Ther Methods Clin Dev. 2014 Oct 22;1:14048. doi: 10.1038/mtm.2014.48. eCollection 2014.

29.

IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.

Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G, Kündig TM, Saudan P, Bachmann MF.

Allergy. 2014 Mar;69(3):338-47. doi: 10.1111/all.12327. Epub 2013 Dec 19. Erratum in: Allergy. 2014 Aug;69(8):1118.

PMID:
24354793
30.

Bacterially produced recombinant influenza vaccines based on virus-like particles.

Jegerlehner A, Zabel F, Langer A, Dietmeier K, Jennings GT, Saudan P, Bachmann MF.

PLoS One. 2013 Nov 18;8(11):e78947. doi: 10.1371/journal.pone.0078947. eCollection 2013.

31.

Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.

Skibinski DA, Hanson BJ, Lin Y, von Messling V, Jegerlehner A, Tee JB, Chye de H, Wong SK, Ng AA, Lee HY, Au B, Lee BT, Santoso L, Poidinger M, Fairhurst AM, Matter A, Bachmann MF, Saudan P, Connolly JE.

PLoS One. 2013 Oct 18;8(10):e76571. doi: 10.1371/journal.pone.0076571. eCollection 2013.

32.

Plasmodium vivax malaria vaccines: why are we where we are?

Reyes-Sandoval A, Bachmann MF.

Hum Vaccin Immunother. 2013 Dec;9(12):2558-65. doi: 10.4161/hv.26157. Epub 2013 Aug 26. Review.

33.

Virus-induced humoral immunity: on how B cell responses are initiated.

Zabel F, Kündig TM, Bachmann MF.

Curr Opin Virol. 2013 Jun;3(3):357-62. doi: 10.1016/j.coviro.2013.05.004. Epub 2013 Jun 1. Review.

PMID:
23731601
34.

Active immunotherapy for chronic diseases.

Bachmann MF, Whitehead P.

Vaccine. 2013 Apr 3;31(14):1777-84. doi: 10.1016/j.vaccine.2013.02.001. Epub 2013 Feb 14. Review.

PMID:
23415932
35.

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA.

J Allergy Clin Immunol. 2013 Mar;131(3):866-74. doi: 10.1016/j.jaci.2012.12.1561. Epub 2013 Feb 4.

PMID:
23384679
36.

A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis.

Tissot AC, Spohn G, Jennings GT, Shamshiev A, Kurrer MO, Windak R, Meier M, Viesti M, Hersberger M, Kündig TM, Ricci R, Bachmann MF.

Eur J Immunol. 2013 Mar;43(3):716-22. doi: 10.1002/eji.201242687. Epub 2013 Jan 28.

37.

Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses.

Bessa J, Zabel F, Link A, Jegerlehner A, Hinton HJ, Schmitz N, Bauer M, Kündig TM, Saudan P, Bachmann MF.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20566-71. doi: 10.1073/pnas.1206970109. Epub 2012 Nov 20.

38.

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.

Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, Michielin O, Bachmann MF, Speiser DE.

Eur J Immunol. 2012 Nov;42(11):3049-61. doi: 10.1002/eji.201142361. Epub 2012 Aug 28. Erratum in: Eur J Immunol. 2016 Feb;46(2):493. Eur J Immunol. 2016 Feb;46(2):493.

39.

Immunization strategies for Clostridium difficile infections.

Rebeaud F, Bachmann MF.

Expert Rev Vaccines. 2012 Apr;11(4):469-79. doi: 10.1586/erv.12.18. Review.

PMID:
22551032
40.

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):863-9. doi: 10.1002/eji.201041225.

41.

Taurine: energy drink for T cells.

Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):819-21. doi: 10.1002/eji.201242450.

42.

Innate immunity mediates follicular transport of particulate but not soluble protein antigen.

Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF.

J Immunol. 2012 Apr 15;188(8):3724-33. doi: 10.4049/jimmunol.1103312. Epub 2012 Mar 16.

43.

Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody.

Tars K, Kotelovica S, Lipowsky G, Bauer M, Beerli RR, Bachmann MF, Maurer P.

J Mol Biol. 2012 Jan 6;415(1):118-27. doi: 10.1016/j.jmb.2011.10.042. Epub 2011 Nov 3.

PMID:
22079050
44.

Virus-like particles induce robust human T-helper cell responses.

Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P.

Eur J Immunol. 2012 Feb;42(2):330-40. doi: 10.1002/eji.201142064. Epub 2011 Dec 2.

45.

Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression.

Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer HD, Johansen P, Senti G, Contassot E, Bachmann MF, French LE, Oxenius A, Kündig TM.

Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18055-60. doi: 10.1073/pnas.1109176108. Epub 2011 Oct 17.

46.

Therapeutic vaccines for chronic diseases: successes and technical challenges.

Bachmann MF, Jennings GT.

Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2815-22. doi: 10.1098/rstb.2011.0103. Review.

47.

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Lüönd R, Ortmann R, Reichwald J, Zurini M, Mir A, Bachmann MF, Staufenbiel M.

J Neurosci. 2011 Jun 22;31(25):9323-31. doi: 10.1523/JNEUROSCI.0293-11.2011.

48.

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.

Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P, Renner WA, Bachmann MF.

Clin Exp Allergy. 2011 Sep;41(9):1305-12. doi: 10.1111/j.1365-2222.2011.03783.x. Epub 2011 Jun 14.

PMID:
21672053
49.

Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis.

Freigang S, Ampenberger F, Spohn G, Heer S, Shamshiev AT, Kisielow J, Hersberger M, Yamamoto M, Bachmann MF, Kopf M.

Eur J Immunol. 2011 Jul;41(7):2040-51. doi: 10.1002/eji.201041316. Epub 2011 Jun 8.

50.

Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.

Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL.

Immunity. 2011 Mar 25;34(3):375-84. doi: 10.1016/j.immuni.2011.01.011. Epub 2011 Feb 25.

Supplemental Content

Loading ...
Support Center